COMP <GO>
FULC vs IRD // EV/EBITDA & P/E VALUATION
Fulcrum Therapeutics Inc. (NASDAQ) VS. Opus Genetics Inc. (NASDAQ) • 15-METRIC TALLY: FULC 1
— IRD 3
■ METRIC PARITY
LAST: $3.77 (+0.53%) • MKT CAP: $288.0M
valuation
—
LAST: $3.65 (-0.81%) • MKT CAP: $303.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FULC VS. IRD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FULC | IRD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.97% | -11.61% | -9.36 | IRD | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 29.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | IRD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 39.7 | +9.10 | FULC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $288.0M | $303.7M | -$15.7M | IRD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FULC REV | IRD REV | FULC GROSS % | IRD GROSS % | FULC FCF | IRD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $14.2M | — | — | -$60.4M | -$35.3M |
| FY 2024 | $0 | $11.0M | — | — | -$2.5M | -$25.6M |
| FY 2023 | $0 | $19.0M | — | — | -$91.0M | -$1.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FULC // BETA —
IRD // BETA —